Challenge Your Exam Readiness With Our Free AOCNP Practice Questions

Carboplatin at AUC ≥4 is considered at least moderately emetogenic and benefits from NK1 receptor antagonist augmentation. Optimal prophylaxis includes a 5-HT3 receptor antagonist (e.g., palonosetron), dexamethasone, and an NK1 antagonist (aprepitant/fosaprepitant or netupitant when combined with palonosetron). Olanzapine (typically 5–10 mg) further improves control of both nausea and emesis and is reasonable when prior cycles showed bothersome symptoms. Palonosetron + dexamethasone alone (Option A) undercovers substance P–mediated pathways and increases delayed-phase failure. Scopolamine (Option C) targets vestibular nausea and is not primary for chemotherapy-induced nausea/vomiting. Dexamethasone alone (Option D) is inadequate. The APRN should check interaction profiles (CYP3A4 with NK1s), adjust dexamethasone dose if using netupitant (due to steroid-sparing effect), provide a rescue plan (prochlorperazine or metoclopramide), and reinforce nonpharmacologic measures (small frequent meals, hydration). Document prior cycle outcomes to tailor future prophylaxis and schedule follow-up to capture breakthrough events promptly.